Retrospective Survey of Bone Fracture in Post-Menopausal Breast Cancer Patients With Arimidex 1 mg as Adjuvant Therapy
N/A
N/A
N/A
N/A
N/A
Not Enrolling
Female
Breast Cancer
Female
Breast Cancer
Trial Information
Retrospective Survey of Bone Fracture in Post-Menopausal Breast Cancer Patients With Arimidex 1 mg as Adjuvant Therapy
Inclusion Criteria:
- Post-menopausal breast cancer patients treated with Arimidex 1mg at the time of
previously conducted clinical experience investigation.
Exclusion Criteria:
-
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
Bone fracture incidence
Outcome Time Frame:
Time since starting Arimidex
Safety Issue:
Yes
Principal Investigator
AstraZeneca Japan Medical Director MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca
Authority:
Japan: Institutional Review Board
Study ID:
NIS-OJP-ARI-2007/1
NCT ID:
NCT00859560
Start Date:
January 2008
Completion Date:
December 2008
Related Keywords:
- Breast Cancer
- Breast cancer
- post-menopausal women
- Arimidex
- bone fracture
- Breast Neoplasms
- Fractures, Bone
Name | Location |
|---|
